Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-08-20 5:41 pm Purchase | 2025-08-13 | 13G | X4 Pharmaceuticals, Inc. XFOR | BIOTECHNOLOGY VALUE FUND L P | 2,243,659 9.900% | 2,243,659 (New Position) | Filing History |
| 2025-08-19 4:05 pm Purchase | 2025-08-12 | 13G | X4 Pharmaceuticals, Inc. XFOR | Deep Track Biotechnology Master Fund, Ltd. | 2,366,995 9.990% | 2,366,995 (New Position) | Filing History |
| 2025-08-18 5:00 pm Purchase | 2025-08-11 | 13G | X4 Pharmaceuticals, Inc. XFOR | Trails Edge Capital Partners, LP | 2,317,153 9.900% | 2,317,153 (New Position) | Filing History |
| 2025-08-18 4:26 pm Purchase | 2025-08-11 | 13D | X4 Pharmaceuticals, Inc. XFOR | Coastlands Capital LP | 2,479,645 9.990% | 2,479,645 (New Position) | Filing History |
| 2025-08-15 4:54 pm Purchase | 2025-08-13 | 13D | X4 Pharmaceuticals, Inc. XFOR | Growth Equity Opportunities 18 VGE, LLC | 2,243,658 9.990% | 2,243,658 (New Position) | Filing History |
| 2025-08-14 5:53 pm Sale | 2025-06-30 | 13G | X4 Pharmaceuticals, Inc. XFOR | ORBIMED ADVISORS LLC | 134,947 1.700% | -248,201 (-64.78%) | Filing History |
| 2025-08-13 9:40 pm Purchase | 2025-08-11 | 13D | X4 Pharmaceuticals, Inc. XFOR | Bain Capital Life Sciences Fund, L.P. | 2,436,526 9.990% | 2,436,526 (New Position) | Filing History |
| 2025-07-18 11:48 am Purchase | 2025-06-30 | 13G | X4 Pharmaceuticals, Inc. XFOR | BlackRock Inc. BLK | 179,125 3.000% | 179,125 (New Position) | Filing History |
| 2025-01-31 10:09 am Sale | 2024-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR | VANGUARD GROUP INC | 273,363 4.800% | -7,994 (-2.84%) | Filing History |
| 2024-11-12 5:59 pm Unchanged | 2024-09-30 | 13G | X4 Pharmaceuticals, Inc. XFOR | VANGUARD GROUP INC | 281,358 5.000% | 0 (Unchanged) | Filing History |
| 2024-11-08 2:17 pm Unchanged | 2024-09-30 | 13G | X4 Pharmaceuticals, Inc. XFOR | BlackRock Inc. BLK | 373,689 6.700% | 0 (Unchanged) | Filing History |
| 2024-11-04 2:15 pm Purchase | 2024-09-30 | 13G | X4 Pharmaceuticals, Inc. XFOR | VANGUARD GROUP INC | 281,358 5.000% | 281,358 (New Position) | Filing History |
| 2024-10-22 6:06 pm Purchase | 2024-09-30 | 13G | X4 Pharmaceuticals, Inc. XFOR | BlackRock Inc. BLK | 373,689 6.700% | 101,664 (+37.37%) | Filing History |
| 2024-02-14 7:36 pm Purchase | 2023-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR | ORBIMED ADVISORS LLC | 383,148 6.700% | 38,860 (+11.29%) | Filing History |
| 2024-02-14 4:44 pm Purchase | 2022-06-30 | 13G | X4 Pharmaceuticals, Inc. XFOR | ACORN BIOVENTURES, L.P. | 591,862 9.990% | 591,862 (New Position) | Filing History |
| 2024-02-14 4:32 pm Sale | 2023-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR | Lincoln Park Capital Fund LLC | 53,338 0.947% | -6,998 (-11.60%) | Filing History |
| 2024-02-13 6:55 pm Purchase | 2023-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR | Bain Capital Life Sciences Fund, L.P. | 563,859 11.000% | 157,109 (+38.63%) | Filing History |
| 2024-02-07 5:09 pm Sale | 2024-01-31 | 13G | X4 Pharmaceuticals, Inc. XFOR | BlackRock Inc. BLK | 272,025 4.900% | -8,559 (-3.05%) | Filing History |
| 2024-01-31 2:08 pm Purchase | 2023-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR | BlackRock Inc. BLK | 280,584 5.000% | 244,768 (+683.40%) | Filing History |
| 2024-01-16 4:18 pm Sale | 2023-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR | Integrated Core Strategies (US) LLC | 55,477 1.000% | -220,150 (-79.87%) | Filing History |